Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening | NEJM
Original Article from The New England Journal of Medicine — Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
Related Articles
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel | NEJM
The autologous cellular therapy exagamglogene autotemcel is generated by editing an erythroid-specific enhancer of BCL11A. Could another site be edited unintentionally? This study gauged the…
FFR-Guided Complete PCI for STEMI | NEJM
Quick Take Video Summary from The New England Journal of Medicine — FFR-Guided Complete PCI for STEMI
Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria | NEJM
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcut…
Welcoming the Era of Gene Editing in Medicine | NEJM
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Small-Bowel Bleeding | NEJM
Abdominal pain and large-volume hematochezia developed in a man who was in the hospital for a ruptured cerebral aneurysm. Findings on endoscopy and colonoscopy were…
Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria | NEJM
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcut…
Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine | NEJM
Review Article from The New England Journal of Medicine — Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine
Beyond Code Status | NEJM
Despite being absolutely clear that she wanted a quick, painless end of life, a geriatrician’s elderly mother receives aggressive care. How can we ensure that…
Welcoming the Era of Gene Editing in Medicine | NEJM
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia | NEJM
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Ca…